AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32184312 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anti-reflux surgery
Number of subjects: 0
Study 32184340 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and magnetic resonance spectroscopy (MRS) biomarkers
Number of subjects: 104
Study 32184340 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 104
Study 32184375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation defined as arterial blood gas (ABG) ≤ 35 mm Hg
Number of subjects: 112
Study 32184375 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant hyperventilation defined as ABG ≤ 30 mm Hg
Number of subjects: 112
Study 32184375 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme hyperventilation defined as ABG ≤ 25 mm Hg
Number of subjects: 112
Study 32184556 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 Ahmed glaucoma valve
Number of subjects: 56
Study 32184556 — intervention group
Group type: EXPERIMENTAL
Intervention: FP7 Ahmed glaucoma valve
Number of subjects: 56
Study 32184653 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane (3 mL)
Number of subjects: 272
Study 32184653 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic treatment (SAT; IV paracetamol 1g or ketoprofen 100mg for moderate pain [NRS 4-6] and IV morphine 0.1mg/kg for severe pain [NRS ≥7])
Number of subjects: 272
Study 32184653 — intervention group
Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 272
Study 32184889 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training with Eye-Cervical Re-education Program
Number of subjects: 0
Study 32184889 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-Cervical Re-education Program
Number of subjects: 0
Study 32185074 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap-sliding technique
Number of subjects: 15
Study 32185462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive leg (one-legged physical inactivity)
Number of subjects: 10
Study 32185685 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Number of subjects: 0
Study 32185745 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI) 80 U twice weekly for 12 weeks
Number of subjects: 259
Study 32185745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 32186413 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal Medicine SH003
Number of subjects: 0
Study 32187112 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR treatment duration >12 months
Number of subjects: 533
Study 32187112 — intervention group
Group type: COMPARATOR
Intervention: BUP-XR treatment duration ≤2 months
Number of subjects: 533
Study 32187112 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR treatment
Number of subjects: 533
Study 32187142 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-scope balloon-assisted enteroscopy (TTS-BAE) using NaviAid AB device (anterograde approach)
Number of subjects: 34
Study 32187142 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-scope balloon-assisted enteroscopy (TTS-BAE) using NaviAid AB device (retrograde approach)
Number of subjects: 34
Study 32187142 — intervention group
Group type: EXPERIMENTAL
Intervention: NaviAid AB enteroscopy
Number of subjects: 34
Study 32187457 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (25 mg/m², oral, twice daily, continuous dosing schedule, 28-day cycles)
Number of subjects: 50
Study 32187630 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF) with Medigus ultrasonic surgical endostapler (MUSE)
Number of subjects: 37
Study 32187883 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine (30 mg/m²)
Number of subjects: 18
Study 32188417 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA and dexamethasone (12 mg intravenously)
Number of subjects: 149
Study 32188473 — intervention group
Group type: EXPERIMENTAL
Intervention: High HGF expression
Number of subjects: 720
Study 32188473 — intervention group
Group type: EXPERIMENTAL
Intervention: High CXCL12 expression
Number of subjects: 720
Study 32188473 — intervention group
Group type: COMPARATOR
Intervention: Low HGF expression
Number of subjects: 720
Study 32188473 — intervention group
Group type: COMPARATOR
Intervention: Low CXCL12 expression
Number of subjects: 720
Study 32188491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 384
Study 32188491 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-partum
Number of subjects: 384
Study 32188508 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA)
Number of subjects: 0
Study 32188593 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement (4 g/day eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) as ethyl esters)
Number of subjects: 38
Study 32188593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 g/day olive oil)
Number of subjects: 38
Study 32188704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously every 21 days
Number of subjects: 127
Study 32188717 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32188971 — intervention group
Group type: EXPERIMENTAL
Intervention: IMMY lateral flow assay (LFA)
Number of subjects: 239
Study 32188971 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactomannan detection
Number of subjects: 239
Study 32188971 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM Diagnostics lateral flow device (LFD)
Number of subjects: 239
Study 32188971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LFA and β-D-glucan test
Number of subjects: 239
Study 32188971 — intervention group
Group type: EXPERIMENTAL
Intervention: LFA after omitting serum galactomannan
Number of subjects: 239
Study 32189217 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin-pretreated samples from control group
Number of subjects: 3
Study 32189217 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin-pretreated samples from AMA group
Number of subjects: 3
Study 32189217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin-pretreated samples from MO women
Number of subjects: 3
Study 32189217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin-naïve samples from MO women
Number of subjects: 3
Study 32189575 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum IVC diameter measured in M-mode
Number of subjects: 71
Study 32189575 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in maximum IVC diameter measured in B-mode
Number of subjects: 71
Study 32190333 — intervention group
Group type: EXPERIMENTAL
Intervention: HRVB + APA
Number of subjects: 70
Study 32190333 — intervention group
Group type: COMPARATOR
Intervention: APA alone
Number of subjects: 70
Study 32190413 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 1105
Study 32190413 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 1105
Study 32190808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Guidelines for Americans (DGA)
Number of subjects: 0
Study 32190808 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical American Diet (TAD)
Number of subjects: 0
Study 32190809 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Grain (WG) exposure
Number of subjects: 0
Study 32190809 — intervention group
Group type: COMPARATOR
Intervention: Refined Grain (RG) exposure
Number of subjects: 0
Study 32190892 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D3 (25(OH)D3) concentrations
Number of subjects: 1169
Study 32190892 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium intake (Q3 vs. Q1)
Number of subjects: 1169
Study 32190892 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium intake (Q4 vs. Q1)
Number of subjects: 1169
Study 32190892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sufficient 25(OH)D3 (≥50 nmol/L) and high magnesium intake
Number of subjects: 1169
Study 32190892 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 1169
Study 32191209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE) with cold Belzer solution (4-10°C) and continuous oxygenation (partial pressure of oxygen of 500-600 mm Hg)
Number of subjects: 220
Study 32191209 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (SCS) with Celsior solution stored on ice
Number of subjects: 220
Study 32191330 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus oral vinorelbine
Number of subjects: 30
Study 32191645 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe receptor insulin resistance (INSR)
Number of subjects: 38
Study 32191646 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese-NL (n = 24)
Number of subjects: 60
Study 32191646 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese-NAFLD (n = 22)
Number of subjects: 60
Study 32191646 — intervention group
Group type: COMPARATOR
Intervention: Lean-NL (n = 14)
Number of subjects: 60
Study 32191646 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese-NL and Obese-NAFLD
Number of subjects: 60
Study 32191763 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission testing for toxigenic C. difficile colonization
Number of subjects: 62760
Study 32191763 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing admission surveillance
Number of subjects: 62760
Study 32192431 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-atracurium 150, 100, 70, 50, 30, and 20 μg·kg
Number of subjects: 23
Study 32192445 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel test for assessing the effect of genetic markers on drug immunogenicity
Number of subjects: 0
Study 32192445 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel test for analyzing drug immunogenicity
Number of subjects: 0
Study 32192445 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel test for testing the equality of improper survival distributions of semi-continuous outcomes
Number of subjects: 0
Study 32192573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously over 60 min on days 1 and 15 of a 28-day cycle (part A)
Number of subjects: 85
Study 32192573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (recommended phase 2 dose) (part B)
Number of subjects: 85
Study 32192573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (part B)
Number of subjects: 85
Study 32192650 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 158
Study 32192650 — intervention group
Group type: COMPARATOR
Intervention: Diabetic recipients (DM)
Number of subjects: 158
Study 32192650 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic recipients (non-DM)
Number of subjects: 158
Study 32192666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Amiodarone
Number of subjects: 0
Study 32192689 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut R/Evolut PRO valves
Number of subjects: 411
Study 32192689 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN 3 valves
Number of subjects: 411
Study 32192693 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable transcatheter heart valve (THV)
Number of subjects: 200
Study 32192693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional THV crimping
Number of subjects: 200
Study 32192746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 12 months
Number of subjects: 8757
Study 32192746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 2 years
Number of subjects: 8757
Study 32192746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality at 2 years
Number of subjects: 8757
Study 32192746 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite major adverse cardiovascular events (MACE) at 2 years
Number of subjects: 8757
Study 32192746 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding at 2 years
Number of subjects: 8757
Study 32192746 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of death and MACE by type of ACS
Number of subjects: 8757
Study 32192746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality and bleeding comparison by region
Number of subjects: 8757
Study 32192948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist education and intervention
Number of subjects: 321
Study 32192948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist education
Number of subjects: 321
Study 32192948 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey completion
Number of subjects: 321
Study 32193248 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 193
Study 32193248 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 193
Study 32193258 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent medical evaluation by an experienced GP at 6 months of unremitting sick leave
Number of subjects: 937
Study 32193268 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-based genetic test referral
Number of subjects: 0
Study 32193268 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted genetic testing based on clinical prediction models
Number of subjects: 0
Study 32193268 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted genetic testing based on biomarkers
Number of subjects: 0
Study 32193268 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanket genetic testing
Number of subjects: 0
Study 32193268 — intervention group
Group type: COMPARATOR
Intervention: No genetic testing
Number of subjects: 0
Study 32193378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PARP (niraparib) and PD-1 (pembrolizumab) inhibition
Number of subjects: 0
Study 32193623 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal canal hypermetabolism in males
Number of subjects: 613
Study 32193623 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI in patients with anal canal hypermetabolism
Number of subjects: 613
Study 32193623 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for anal canal hypermetabolism
Number of subjects: 613
Study 32193785 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based lifestyle intervention programs
Number of subjects: 182
Study 32193785 — intervention group
Group type: EXPERIMENTAL
Intervention: logistic regression analysis
Number of subjects: 182
Study 32193837 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 3411
Study 32193837 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 3411
Study 32193837 — intervention group
Group type: COMPARATOR
Intervention: Background treatment with metformin (MET) alone or MET + SU
Number of subjects: 3411
Study 32193971 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTA Vascular Closure Device
Number of subjects: 0
Study 32193971 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32193990 — intervention group
Group type: EXPERIMENTAL
Intervention: CTAG Stent-Graft with the Active Control System
Number of subjects: 0
Study 32194490 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (one session before surgery)
Number of subjects: 400
Study 32194490 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 400
Study 32195186 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet combination of Trastuzumab, Lapatinib, and Chemotherapy
Number of subjects: 0
Study 32195932 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting beads transarterial chemoembolization (DEB-TACE)
Number of subjects: 37
Study 32196557 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP14
Number of subjects: 141
Study 32196557 — intervention group
Group type: EXPERIMENTAL
Intervention: Model integrating MTV and MH
Number of subjects: 141
Study 32197614 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infected subjects (n=34)
Number of subjects: 58
Study 32197614 — intervention group
Group type: COMPARATOR
Intervention: H. pylori uninfected subjects (n=24)
Number of subjects: 58
Study 32197614 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradicated subjects (n=22)
Number of subjects: 58
Study 32197614 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 58
Study 32197614 — intervention group
Group type: COMPARATOR
Intervention: H. pylori infected vs uninfected subjects
Number of subjects: 58
Study 32197630 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous MSCs (0.5-2 × 10^6 cells) after surgical scar resection
Number of subjects: 16
Study 32197630 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of autologous MSCs
Number of subjects: 16
Study 32198598 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin concentrations in overweight and obese patients
Number of subjects: 62
Study 32198598 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA levels in overweight and obese patients
Number of subjects: 62
Study 32198598 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels in overweight and obese patients
Number of subjects: 62
Study 32198598 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic pulse pressure in patients with BMI ≥ 25 kg/m²
Number of subjects: 62
Study 32198598 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin concentrations and LVMI/PWV relationship
Number of subjects: 62
Study 32198674 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous fiber supplementation
Number of subjects: 1347
Study 32198837 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO stents
Number of subjects: 3614
Study 32198847 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative changes in medial meniscus position and morphology measured via magnetic resonance imaging (MRI) before knee replacement and 2 years prior.
Number of subjects: 70
Study 32198847 — intervention group
Group type: COMPARATOR
Intervention: Control knees without subsequent knee replacement (KR).
Number of subjects: 70
Study 32199395 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairment
Number of subjects: 206
Study 32199395 — intervention group
Group type: EXPERIMENTAL
Intervention: Other predisposing risk factors for delirium
Number of subjects: 206
Study 32199395 — intervention group
Group type: EXPERIMENTAL
Intervention: Predisposition for delirium
Number of subjects: 206
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity measured on a 0-10 Numerical Rating Scale
Number of subjects: 10000
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain distribution reported on a body Manikin
Number of subjects: 10000
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain quality assessed using the McGill Pain Questionnaire
Number of subjects: 10000
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Central aspects of pain measured using CAP-Knee
Number of subjects: 10000
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessed based on Fried criteria
Number of subjects: 10000
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability assessed using the FRAIL questionnaire
Number of subjects: 10000
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture risk assessment
Number of subjects: 10000
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class analysis for identifying discrete subgroups and trajectories
Number of subjects: 10000
Study 32199451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of recruitment bias
Number of subjects: 10000
Study 32199466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 62
Study 32200083 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' meetings to optimize bowel preparation
Number of subjects: 1524
Study 32200083 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and oral instructions to patients
Number of subjects: 1524
Study 32200083 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to gastroenterology unit
Number of subjects: 1524
Study 32200083 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose regimens
Number of subjects: 1524
Study 32200083 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-liter polyethylene glycol-based bowel purge
Number of subjects: 1524
Study 32200083 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% or more intake of bowel preparation
Number of subjects: 1524
Study 32200083 — intervention group
Group type: COMPARATOR
Intervention: Bedridden status
Number of subjects: 1524
Study 32200083 — intervention group
Group type: COMPARATOR
Intervention: Constipation
Number of subjects: 1524
Study 32200083 — intervention group
Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 1524
Study 32200083 — intervention group
Group type: COMPARATOR
Intervention: Use of anti-psychotic drugs
Number of subjects: 1524
Study 32200083 — intervention group
Group type: COMPARATOR
Intervention: 7 or more days of hospitalization
Number of subjects: 1524
Study 32200138 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily until radiological progression or death
Number of subjects: 199
Study 32200138 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily
Number of subjects: 199
Study 32200498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) levels in participants with rapid decline in e-GFR
Number of subjects: 912
Study 32200498 — intervention group
Group type: EXPERIMENTAL
Intervention: Average decline in e-GFR
Number of subjects: 912
Study 32200512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg
Number of subjects: 206
Study 32200714 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD subjects
Number of subjects: 33
Study 32200714 — intervention group
Group type: COMPARATOR
Intervention: Non-PAD subjects
Number of subjects: 33
Study 32200718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Patterns (DPs) identified as 'alcohol', 'fast food and alcohol', 'fried, processed, and dairy products', 'meat, starch, sodas, and fat' in G1 and G2 men and women.
Number of subjects: 1527
Study 32200718 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Alcohol' DP in G1 men.
Number of subjects: 1527
Study 32200854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibitors
Number of subjects: 0